Syntarga BV, a spin-out of Radboud University, Nijmegen, which is developing technology for linking antibodies to cancer drugs, has raised venture funding from the public fund, PPM Oost.
“Syntarga’s [technology] can be applied to existing and new antibodies. This is specific expertise, and is of great importance in the development of cancer drugs,” said Ron Ward, deputy director of PPM Oost.
PPM Oost Netherlands NV, based in Arnhem and Enschede, invests public funds in promising companies that it thinks will contribute to a thriving economy in the eastern Netherlands. The fund has over €100 million under management.